Orexigen Resurrects Contrave With New Trial Agreement With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech breathes new life into its obesity program now that it has reached agreement with FDA on a two-year cardiovascular safety study for Contrave.